Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE).
Pablo E PergolaMichael DavidsonCamilla JensenAmir A Mohseni ZonooziDominic S RajPhilip Andreas SchytzKatherine R TuttleVlado PerkovicPublished in: Journal of the American Society of Nephrology : JASN (2023)
Anti-inflammatory therapy with ziltivekimab improved the markers of anemia and iron homeostasis in people with stage 3-5 CKD and systemic inflammation, suggesting a possible role in anemia management.